If a political debate takes place this year on the topic of ACA cost containment and the affordability of premiums, it’s hoped that reform initiatives won’t be piecemeal.

A new mRNA-based method reprograms immune cells directly inside solid tumors, boosting anti-cancer activity and paving the way for next-generation therapies.

Convenience of an oral pill may be critical to some patients. This could expand the market but also improve patient persistence and sustainability of long-term outcomes.

A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the future of genetic medicine and patient care.

Differences in vaccination policies illustrate the importance of context, regarding distinct healthcare systems and the vaccine stance taken by public health officials.

Childhood vaccine schedules among U.S. peers differ marginally. Unlike the U.S., however, peer health officials don’t sow doubt among the public about vaccination.

Medicare’s cap on out-of-pocket costs helps cancer patients and others taking expensive drugs. With less financial burden, patients can better afford their medications.

It isn’t wrong to promote healthier living. But misinforming the public on the flu vaccine and downplaying the disease’s impact aren’t in public health’s interest.

At least 12% of adults in the U.S. have been prescribed a glucagon‐like peptide‐1 drug for one or multiple indications, but 54% of users report affordability challenges.

Significant changes to public health infrastructure, the healthcare system and economy in 2025 won’t end as we flip the calendar. Disruption will continue in 2026.